Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company that creates long-acting monoclonal antibodies and combination therapies to treat inflammatory bowel disease and rheumatic conditions. Its drug development pipeline targets biological pathways including α4β7, TL1A, and IL-23, which are being advanced as individual therapies as well as fixed-dose pairwise combinations. The company focuses on conditions such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Because its product candidates remain in clinical evaluation, Spyre does not currently sell commercial products, though its prospective end-users are individuals suffering from these chronic immune-mediated disorders.

The company operates with 102 full-time employees and does not own or run its own manufacturing, testing, storage, or distribution facilities. Instead, it relies entirely on third-party contract facilities and external service providers across the United States and internationally, including China, while establishing additional domestic supplier redundancies. The provided text details operations across these clinical and manufacturing partners, but it does not specify the location of the company's corporate headquarters.

Summary of the business section of Spyre Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 102 employees, all of whom were employed full time.”